Background: Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE has become a cornerstone in the management of neuroendocrine tumors (NETs). However, the efficiency of this targeted therapy is highly dependent on the radiopharmaceutical drug delivery system and its infusion kinetics, which influence systemic biodistribution and therapeutic efficacy. This study evaluates various gravity-based infusion fluid dynamics to optimize the drug delivery profile, ensuring standardized delivery while minimizing residual activity. Methods: A retrospective analysis of 127 administrations of 177Lu-DOTATATE (7.4 GBq per cycle) was conducted across 35 patients with NETs to assess vial dilution kinetics. Four distinct infusion rate (IR) strategies were compared to evaluate mass balance and delivery efficiency: constant infusion rate (1-IR); a single rate increase at 10 min (2-IR); two rate increases at 10 and 30 min (3-IR); and three rate increases at 10, 30, and 40 min (4-IR). Results: Stepwise increases in the IR significantly accelerated the vial clearance kinetics and reduced radiopharmaceutical stagnation within the infusion lines. Successful delivery of the target dose (98% of the pre-infusion activity measured in each specific vial) was achieved in 56% of cases with the 1-IR protocol (9 injections) and increased to 87% with 2-IR (45 injections), 97% with 3-IR (60 injections), and 100% with 4-IR (13 injections). Conclusions: Modulating fluid dynamics through stepwise IR protocols significantly enhances radiopharmaceutical delivery efficiency. The 3-IR protocol offers a favorable balance between procedural efficiency and clinical safety.

Optimization of Gravity Infusion Protocols for 177Lu-DOTATATE Administration in Peptide Receptor Radionuclide Therapy / Grasso, S., Varallo, A., Gaudieri, V., Klain, M., Pastore, R., Arena, S., Oliviero, C., Buono, M., Manzi, D., Schiano, R., Nappi, C., Totaro, P., Bonifacio, R.R., Cuocolo, A., Clemente, S.. - In: PHARMACEUTICS. - ISSN 1999-4923. - 18:7(2026). [10.3390/pharmaceutics18070889]

Optimization of Gravity Infusion Protocols for 177Lu-DOTATATE Administration in Peptide Receptor Radionuclide Therapy

Gaudieri, Valeria;Klain, Michele;Oliviero, Caterina;Buono, Mauro;Manzi, Daniele;Nappi, Carmela;Totaro, Pasquale;Cuocolo, Alberto;Clemente, Stefania
2026

Abstract

Background: Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE has become a cornerstone in the management of neuroendocrine tumors (NETs). However, the efficiency of this targeted therapy is highly dependent on the radiopharmaceutical drug delivery system and its infusion kinetics, which influence systemic biodistribution and therapeutic efficacy. This study evaluates various gravity-based infusion fluid dynamics to optimize the drug delivery profile, ensuring standardized delivery while minimizing residual activity. Methods: A retrospective analysis of 127 administrations of 177Lu-DOTATATE (7.4 GBq per cycle) was conducted across 35 patients with NETs to assess vial dilution kinetics. Four distinct infusion rate (IR) strategies were compared to evaluate mass balance and delivery efficiency: constant infusion rate (1-IR); a single rate increase at 10 min (2-IR); two rate increases at 10 and 30 min (3-IR); and three rate increases at 10, 30, and 40 min (4-IR). Results: Stepwise increases in the IR significantly accelerated the vial clearance kinetics and reduced radiopharmaceutical stagnation within the infusion lines. Successful delivery of the target dose (98% of the pre-infusion activity measured in each specific vial) was achieved in 56% of cases with the 1-IR protocol (9 injections) and increased to 87% with 2-IR (45 injections), 97% with 3-IR (60 injections), and 100% with 4-IR (13 injections). Conclusions: Modulating fluid dynamics through stepwise IR protocols significantly enhances radiopharmaceutical delivery efficiency. The 3-IR protocol offers a favorable balance between procedural efficiency and clinical safety.
2026
Optimization of Gravity Infusion Protocols for 177Lu-DOTATATE Administration in Peptide Receptor Radionuclide Therapy / Grasso, S., Varallo, A., Gaudieri, V., Klain, M., Pastore, R., Arena, S., Oliviero, C., Buono, M., Manzi, D., Schiano, R., Nappi, C., Totaro, P., Bonifacio, R.R., Cuocolo, A., Clemente, S.. - In: PHARMACEUTICS. - ISSN 1999-4923. - 18:7(2026). [10.3390/pharmaceutics18070889]
File in questo prodotto:
File Dimensione Formato  
pharmaceutics-18-00889.pdf

accesso aperto

Descrizione: Articolo in rivista
Tipologia: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 7.28 MB
Formato Adobe PDF
7.28 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/1057732
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact